Catalyst Pharmaceuticals (CPRX) Equity Ratio (2010 - 2026)

Catalyst Pharmaceuticals has reported Equity Ratio for 17 years, with the latest figure at 0.88 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 0.97% year-over-year to 0.88; the trailing twelve-month figure through Mar 2026 stood at 0.88 (up 0.97% YoY), and the FY2025 full-year result was 0.86, up 1.14% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.88, up from 0.86 in the prior quarter.
• The five-year high for Equity Ratio was 0.9 in Q2 2022, with the low at 0.8 in Q4 2022.
• Historically, Equity Ratio has averaged 0.86 across 5 years, with a median of 0.86 in 2024.
• Annual changes were most pronounced in 2022 — Equity Ratio retreated 8.9% — and 2024, when it gained 5.96%.
• Catalyst Pharmaceuticals' Equity Ratio stood at 0.8 in 2022, then grew by 3.16% to 0.83 in 2023, then advanced by 3.58% to 0.85 in 2024, then grew by 1.14% to 0.86 in 2025, then climbed by 2.09% to 0.88 in 2026.
• The last three Equity Ratio figures came in at 0.88 (Q1 2026), 0.86 (Q4 2025), and 0.88 (Q3 2025), per Business Quant data.